Reshaping the HIV treatment and prevention landscape

Vaccines and Specialty high potential late-stage assets add to current growth drivers Infectious Diseases HIV Oncology Immunology / Respiratory Marketed Shingrix Bexsero Menveo Dovato Cabenuva Zejula Blenrep Jemperli# Benlysta Nucala Late-stage RSV Men ABCWY gepotidacin cabotegravir PrEP Zejula^ Blenrep^^ Jemperlit ..... gsk Opportunity Driven depemokimab ('294) otilimab daprodustat Late stage pipeline >£20bn potential PYS NRA* # Tesaro asset *Peak year sales non-risk adjusted, excludes COVID solutions. See basis of preparation and assumptions in Appendix. ^1st line OC combination + NSCLC and breast; ^^MM earlier lines; + 1st line EC 18

View entire presentation